• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cytokine . Prognostic bioindicators in severe COVID-19 patients

tetano

Editor, Senior Moderator
Cytokine


. 2021 Jan 28;141:155455.
doi: 10.1016/j.cyto.2021.155455. Online ahead of print.
Prognostic bioindicators in severe COVID-19 patients


L Bergantini[SUP] 1 [/SUP], E Bargagli[SUP] 2 [/SUP], M d'Alessandro[SUP] 2 [/SUP], R M Refini[SUP] 2 [/SUP], P Cameli[SUP] 2 [/SUP], L Galasso[SUP] 3 [/SUP], C Scapellato[SUP] 3 [/SUP], F Montagnani[SUP] 4 [/SUP], S Scolletta[SUP] 5 [/SUP], F Franchi[SUP] 5 [/SUP], S Valente[SUP] 6 [/SUP], D Bennett[SUP] 2 [/SUP], G Sebastiani[SUP] 7 [/SUP], B Frediani[SUP] 8 [/SUP], F Dotta[SUP] 7 [/SUP]



Affiliations

Abstract

Background: Severe acute respiratory syndrome caused by novel coronavirus 2 (SARS-CoV-2) emerged in Wuhan (China) in December 2019. Here we evaluated a panel of biomarkers to phenotype patients and to define the role of immuno-inflammatory mediators as biomarkers of severity.
Materials and methods: Serum samples were obtained from 24 COVID-19 patients on admission to hospital, before any treatment or infusion of intravenous steroids or invasive ventilation. KL-6 IL-6 and C-peptide were measured by chemiluminescent enzyme immunoassay. IL-6 assay was validated for accuracy and precision. The validity of variables used to distinguish severe from mild-to-moderate patients was assessed by areas under curves (AUC) of the receiver operating characteristic (ROC) and logistic regression was performed to combine parameters of the two groups.
Results: In the severe group, IL-6, CRP and KL-6 concentrations were significantly higher than in mild-to-moderate patients. KL-6, IL-6 and CRP concentrations were directly correlated with each other. ROC curve analysis of the logistic regression model including IL-6, KL-6 and CRP showed the best performance with an AUC of 0.95.
Conclusions: Besides corroborating previous reports of over-expression of IL-6 in severe COVID-19 patients requiring mechanical ventilation, analytical determination of other mediators showed that IL-6 concentrations were correlated with those of KL-6 and CRP. The combination of these three prognostic bioindicators made it possible to distinguish severe COVID-19 patients with poor prognosis from mild-to-moderate patients.

Keywords: Biomarkers; COVID-19; IL-6; KL-6.
 
Back
Top Bottom